Nivolumab (a PD-1 immune checkpoint inhibitor) compared to Everolimus (an mTOR inhibitor) has recently been shown to result in a greater objective response rate (25% vs. 5%) and longer overall survival in ccRCC; however no patients enrolled had pRCC [24]. This evidence concerns the gene MTOR and nonpapillary renal cell carcinoma.